0001209191-21-017590.txt : 20210303
0001209191-21-017590.hdr.sgml : 20210303
20210303215532
ACCESSION NUMBER: 0001209191-21-017590
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RASMUSSEN HENRIK S MD
CENTRAL INDEX KEY: 0001271905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38582
FILM NUMBER: 21712413
MAIL ADDRESS:
STREET 1: 508 WRANGLER DRIVE, SUITE 100
CITY: COPPELL
STATE: TX
ZIP: 75019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allakos Inc.
CENTRAL INDEX KEY: 0001564824
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454798831
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 975 ISLAND DRIVE
STREET 2: SUITE 201
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-597-5002
MAIL ADDRESS:
STREET 1: 975 ISLAND DRIVE
STREET 2: SUITE 201
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001564824
Allakos Inc.
ALLK
0001271905
RASMUSSEN HENRIK S MD
975 ISLAND DRIVE, SUITE 201
REDWOOD CITY
CA
94065
0
1
0
0
Chief Medical Officer
Common Stock
2021-03-03
4
S
0
1952
112.83
D
101819
D
Common Stock
2021-03-03
4
S
0
20000
113.00
D
103771
D
Common Stock
2021-03-03
4
M
0
20000
1.1625
A
123771
D
Common Stock
2021-03-02
4
F
0
1316
117.82
D
103771
D
Common Stock
2021-03-02
4
S
0
20000
117.32
D
105087
D
Common Stock
2021-03-02
4
M
0
20000
1.1625
A
125087
D
Common Stock
2021-03-01
4
S
0
20000
120.66
D
105087
D
Common Stock
2021-03-01
4
M
0
20000
1.1625
A
125087
D
Stock Option (Right to buy)
1.1625
2021-03-03
4
M
0
20000
0.00
D
2027-10-02
Common Stock
20000
332000
D
Stock Option (Right to buy)
1.1625
2021-03-02
4
M
0
20000
0.00
D
2027-10-02
Common Stock
20000
352000
D
Stock Option (Right to buy)
1.1625
2021-03-01
4
M
0
20000
0.00
D
2027-10-02
Common Stock
20000
372000
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.30 to $115.09 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.00 to $116.78 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
Shares withheld to satisfy the tax obligations by the reporting person in connection with the vesting of RSUs.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $115.85 to $121.83 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $117.445 to $126.76 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
On October 2, 2017, the Reporting Person was granted an option to purchase 392,000 ordinary shares pursuant to the Company's 2018 Equity Incentive Plan. The option vests as to one-fourth of the shares on October 2, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Henrik Rasmussen
2021-03-03